Availability of early lunch for ‘Mabthera’ biosimilar in Korea

‘Truxima,’ a biosimilar antibody developed by Celltrion from ‘Mabthera Inj(foreign name: Rituxan),’ got the green light for its early domestic launch as winning a series of patent suits.

Mabthera is a treatment sold by a multinational pharmaceutical company Roche for diseases, such as lymphoma and chronic lymphatic leukemia, recording KRW 35.6 billion sales a year based on IMS.  

Celltrion de...